What the business is, and whether it's a good one at a fair price.
Operates a Contract Research, Development and Manufacturing Organization (CRDMO) that handles outsourced chemistry work for global pharma clients, alongside a smaller Speciality Ingredients business. CRDMO is the dominant earner at Rs 1,772.768 cr (83.5% of segment revenue) with segment EBIT of Rs 1,132.985 cr, covering custom synthesis, fermentation, and process development for both large-pharma and biotech customers, including molecules in late-phase clinical development. Speciality Ingredients contributed Rs 351.565 cr (16.5%) and Rs 179.065 cr in EBIT, supplying ingredients into food, nutraceutical and related end-markets. Total FY26 revenue stood at Rs 2,124.333 cr with a 45.4% EBITDA margin. The biggest input cost is raw materials at 33.6% of revenue, followed by employee cost at 13.3% and other operating expenses at 9.2%. Operations run across 3 plants with 2,282 permanent employees, and the company exports about 85% of its output.
Measured from the filed financials, judged against its Pharmaceuticals & Biotechnology peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from ANTHEM BIOSCIENCES LTD's filed financials and exchange disclosures
ANTHEM BIOSCIENCES LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol ANTHEM.
Yes. Over the trailing twelve months ANTHEM BIOSCIENCES LTD reported a net profit of ₹576 Cr on revenue of ₹2,002 Cr.
Not in the latest reported year — ANTHEM BIOSCIENCES LTD's dividend payout for FY26 was nil.
Effectively yes. It holds ₹222 Cr more cash than debt. Debt stands at 0.02× equity.
On trailing P/E, ANTHEM BIOSCIENCES LTD ranks 168 of 175 in Pharmaceuticals & Biotechnology — cheaper than 4% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session ANTHEM BIOSCIENCES LTD moves 1.27% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by ANTHEM BIOSCIENCES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
